Osteoprotegerin Levels Change During STEMI and Reflect Cardiac Function

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages 1523-1528

  Lindberg, Søren ^a   Jensen, Jan S ^a,b   Hoffmann, Søren ^a   Iversen, Allan Z ^a   Pedersen, Sune H ^a   Mogelvang, Rasmus ^a   Galatius, Søren ^a   Flyvbjerg, Allan ^c   Bjerre, Mette ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; OSTEOPROTEGERIN; TROPONIN I; BIOLOGICAL MARKER;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INTRAOPERATIVE PERIOD; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84919708530     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.08.015     Document Type: Article

References (39)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
2. Reid P., Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009, 88:1-17.
3. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. JClin Endocrinol Metab 2001, 86:631-637.
4. Montagnana M., Lippi G., Danese E., Guidi G.C. The role of osteoprotegerin in cardiovascular disease. Ann Med 2013, 45:254-264.
5. Pedersen S., Mogelvang R., Bjerre M., et al. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012, 123:31-38.
6. Dhore C.R., Cleutjens J.P., Lutgens E., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21:1998-2003.
7. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. JClin Endocrinol Metab 2004, 89:4104-4112.
8. Montecucco F., Steffens S., Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?. Clin Dev Immunol 2007, 2007:75805.
9. Fuernau G., Zaehringer S., Eitel I., et al. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013, 167:2134-2139.
10. Andersen G.O., Knudsen E.C., Aukrust P., et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011, 97:460-465.
11. Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus 2013, 2:658.
12. Levey A.S., Bosch J.P., Lewis J.B., et al. Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Int Med 1999, 130:461-470.
13. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. JAm Soc Echocardiogr 2005, 18:1440-1463.
14. Rasmussen L.M., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006, 154:75-81.
15. Omland T., Drazner M.H., Ueland T., et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007, 49:1392-1398.
16. Ueland T., Dahl C.P., Kjekshus J., et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011, 4:145-152.
17. Helske S., Kovanen P.T., Lindstedt K.A., et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007, 9:357-363.
18. Roysland R., Bonaca M.P., Omland T., et al. Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart 2012, 98:786-791.
19. Erkol A., Pala S., Kirma C., et al. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 2011, 107:857-862.
20. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. JAm Coll Cardiol 2008, 51:627-633.
21. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. JAm Coll Cardiol 2004, 44:1970-1976.
22. Ndrepepa G., Mehilli J., Martinoff S., et al. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. JAm Coll Cardiol 2007, 50:149-156.
23. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
24. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553.
25. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48:561-568.
26. Zhang J., Fu M., Myles D., et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002, 521:180-184.
27. Hofbauer L.C., Shui C., Riggs B.L., et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001, 280:334-339.
28. Mogelvang R., Pedersen S.H., Flyvbjerg A., et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol 2012, 109:515-520.
29. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
30. Vik A., Mathiesen E.B., Brox J., et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. JThromb Haemost 2011, 9:638-644.
31. Mogelvang R., Haahr-Pedersen S., Bjerre M., et al. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013, 99:106-110.
32. Abedin M., Omland T., Ueland T., et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007, 99:513-518.
33. Chia S., Senatore F., Raffel O.C., et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008, 1:415-423.
34. Yamaguchi K., Kinosaki M., Goto M., et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. JBiol Chem 1998, 273:5117-5123.
35. Theoleyre S., Kwan Tat S., Vusio P., et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006, 347:460-467.
36. Standal T., Seidel C., Hjertner O., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002, 100:3002-3007.
37. Mosheimer B.A., Kaneider N.C., Feistritzer C., et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. JClin Endocrinol Metab 2005, 90:2964-2971.
38. Nybo M., Rasmussen L.M. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 2008, 201:33-35.
39. Vik A., Brodin E., Sveinbjornsson B., Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 2007, 98:148-154.